Hubungan antara Kadar Feritin dengan Malondialdehyde pada Pasien Talasemia β Mayor di RSD dr. Soebandi Jember

Trinita Diyah Permatasari; Rini Riyanti; Desie Dwi Wisudanti

doi:10.19184/pk.v7i1.17592

Trinita Diyah Permatasari Fakultas Kedokteran Universitas Jember
Rini Riyanti Fakultas Kedokteran Universitas Jember
Desie Dwi Wisudanti Fakultas Kedokteran Universitas Jember

DOI: https://doi.org/10.19184/pk.v7i1.17592

Abstract

Repeated blood transfusions, increased iron absorption, and ineffective erythropoiesis in major β thalassemia patients lead to iron overload characterized by elevated ferritin levels. Free iron will catalyze reactive oxygen species (ROS) formation by Fenton reaction that cause oxidative stress. Malondialdehyde (MDA) is the lipid peroxidation end product used to measure the oxidative stress. This study aimed to determine the correlation between ferritin levels and MDA levels in major β thalassemia patients at dr. Soebandi Hospital Jember. An analitic observational study with cross sectional study design which the subjects were 15 patients with major β thalassemia in the Pediatric Department at dr. Soebandi Hospital Jember who met inclusion and exclusion criteria. Ferritin levels measured by Enzyme-Linked Fluorescent Immuno Assay (ELFA) method and MDA levels measured by Thiobarbituric Acid Reactive Substances (TBARS) method using spectrophotometer at 535 nm. Data was analyzed with Shapiro Wilk normality test and Pearson correlation test. The mean of ferritin levels was 3540,46±3925,37 ng/mL and MDA levels was 4,77±2,03 nmol/mL. The result showed that there is strong positive correlation between ferritin levels and MDA levels with p value=0,001 and r=0,786 in major β thalassemia patients at dr. Soebandi Hospital Jember.

References

[1] Muncie HL, Campbel JS. Alpha and beta thalassemia. Am Fam Physician. 2009 Aug; 80(4): 339-344.
[2] Hoffbrand AV, Moss PAH. 2013. Kapita Selekta Hematologi. Edisi keenam. Jakarta: EGC; 2013.
[3] Galanello R, Origa R. Beta-thalassemia. OJRD. 2010; 5 (11): 1-15.
[4] Wahidiyat, I. 2006. Genetic Problems at Present and Their Challenges in the Future, Thalassemia as a Model. Paediatrica Indonesiana. [Internet] 2006 Oct [cited 2017 Jun 9];46(10):[189-194]. Available from: https://www.paediatricaindonesiana.org/index.php/paediatricaindonesiana/article/view/927/768.
[5] Kementerian Kesehatan Republik Indonesia. [Internet]. Jakarta: Kementerian Kesehatan Republik Indonesia; 2017 [cited 2017 June 10]. Available from:http:/www.depkes.go.id/article/view/17 050900002/skriningpenting-untuk -cegah-thalassemia.html.
[6] Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. Guidelines for the management of transfusion dependent thalassemia (TDT). 3rd ed. Nicosia: Thalassaemia International Federation; 2014.
[7] Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002 May; 99(10): 3505-3516.
[8] Prabhu R, Prabhu V, Prabhu RS. Iron overload in beta thalassemia. J Biosci Tech. 2009; 1(1): 20-31.
[9] Behrman EF, Kleigman RM, Jenson HB. Nelson textbook of pediatrics. 17th Ed. Philadelphia: WB Saunders; 2000.
[10] Mahdi EA. Relationship between oxidative stress and antioxidant status in beta thalassemia major patients. Acta Chim Pharm Indica. 2014 Aug; 4(3): 137-145.
[11] Suryohudoyo P. Ilmu Kedokteran Molekuler Kapita Selekta: Oksidan, Antioksidan, dan Radikal Bebas. Jakarta: Sagung Seto; 2000.
[12] Aziz BN, Al-Kataan MA, Ali WK. Lipid peroxidation and antioxidant status in β-thalassemic patients : Effect of Iron Overload. Iraqi J Pharm Sci. 2009 Jun; 18(2): 1-7.
[13] Arijanty L, Nasar SS. Masalah nutrisi pada thalassemia. Sari Pediatri. 2003 Jun; 5(1): 21-26.
[14] Andriastuti M, Sari TT, Wahidiyat PA, Putriasih SA. Kebutuhan transfusi darah pasca-splenektomi pada thalassemia mayor. Sari Pediatri. 2011 Dec; 13(4): 244-249.
[15] Potts SJ, Mandleco BL. Pediatric nursing: caring for children and their families. 2nd ed. New York: Thomson Coorporatio; 2007.
[16] Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, et al. Deferasirox, deferiprone, and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011 Jan; 96(1): 41-47.
[17] Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006 May; 107(9): 3436-3441.
[18] Permono HB, Ugrasena IDG. Buku Ajar Hematologi Onkologi Anak. Jakarta: IDAI; 2006.
[19] Departement of Nutrition for Health and Development WHO [Internet]. Geneva: Departement of Nutrition for Health and Development WHO; 2007 [cited 2017 Aug 10]. Available from: http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/9789241596107.pdf
[20] World Health Organization [Internet]. Geneva: World Health Organization; 2011 [cited 2017 Nov 18]. Available from: http://www.who.int/vmnis/indicators/serum_ferritin.pdf
[21] Sengsuk C, Tangvarasittichai O, Chantanaskulwong P, Pimanprom A, Wantaneeyawong S, Choowet A, et al. Association of iron overload with oxidative stress, hepatic damage, and dyslipidemia in transfussion-dependent β-thalassemia/HbE patients. India J Clin Biochem. 2014 Aug; 29(3): 298-305.
[22] Patne AB, Hisalkar PJ, Gaikwad SB, Patil SV. Alterations in antioxidant enzyme status with lipid peroxidation in B thalassemia major patients. Int J of Pharm & Life Sci. 2012 Oct; 3(10): 2003-2006.
[23] Safitri R, Ernawaty J, Karim D. Hubungan kepatuhan transfusi dan konsumsi kelasi besi terhadap pertumbuhan anak dengan thalasemia. JOM. 2015 Oct; 2(2): 1474-1483.
[24] Satria A, Ridar E, Tampubolon L. Hubungan derajat klinis dengan kadar feritin penyandang thalassemia β di RSUD Arifin Achmad. JOM FK. 2016 Oct; 3 (2): 1-9.
[25] Rasool M, Malik A, Jabbar U, Begum I, Qazi MH, Asif M, et al. Effecy of iron overload on renal functions and oxidative stress in beta thalassemia patients. Saudi Med J. 2016 Aug; 37(11): 1239-1242.